VectorY at ESGCT showcasing Innovation in Vectorized Antibody Therapies for CNS Disorders
Amsterdam, the Netherlands, Boston, Massachusetts, and Seattle, Washington – October 2, 2025 – VectorY will be present at the European Society of Gene & Cell Therapy (ESGCT) Conference in Seville on 7 – 10 Oct, 2025. Our team will showcase five posters that highlight our recent advances in the development of Vectorized Antibody therapies to treat neurodegenerative diseases.
Poster Presentations:
P0110: Identification of a novel promoter with high CNS expression and superior AAV quality using the baculovirus/insect cell production platform
P0309: AAV-Delivered Anti-PC-OxPL Antibody Fragments as A Novel Therapeutic Approach to Target ALS
P0324: Targeting misfolded mutant HTT protein with vectorized antibodies for the treatment of Huntington Disease
P0334: AAV-mediated delivery of an intrabody targeting TDP-43 for Amyotrophic Lateral Sclerosis therapy
P0924: Optimized insect cell/baculovirus platform for AAV manufacturing: Excellent quality, consistency, and scale-up performance
These studies reflect our commitment to pioneering CNS-targeted delivery, antibody-based therapeutics, and robust AAV manufacturing platforms, key components for advancing transformative treatments.
Meet us at ESGCT 2025 to learn more about our science, connect with our team, and explore how VectorY is working to bring meaningful therapies closer to patients.